Cargo Therapeutics Announces Appointment of Michael Ports, Ph D, As Chief Scientific Officer

Sep 12, 2023•almost 2 years ago

Position

Chief Scientific Officer

Company

Cargo Therapeutics

Michael Ports

San MateoBiotechnology

Description

SAN MATEO, Calif., Sept. 12, 2023 -- CARGO Therapeutics, Inc. , a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Michael Ports, PhD, as Chief Scientific Officer

Company Information

Company

Cargo Therapeutics

Location

1900 ALAMEDA DE LAS PULGAS SUITE 350

San Mateo, California, United States

About

Cargo Therapeutics is a biopharmaceutical company focused on developing CAR-T cell therapies for blood cancers. The company recently faced significant challenges with the discontinuation of its therapy firi-cabtagene autoleucel. After experiencing large layoffs, Cargo was seeking acquisition opportunities.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Ginna hidden

hidden

Michael hidden